Treatment sequencing in metastatic renal cell carcinoma (mRCC)
Treatment sequencing in metastatic renal cell carcinoma (mRCC)
Dr Roberto Iacovelli
Dr Roberto Iacovelli brings you his interpretation of the data when deciding upon the best approach to treatment sequencing in mRCC.
Dr Roberto Iacovelli
Medical Oncologist
Fondazione Policlinico Gemelli IRCCS
Italy
Dr Roberto Iacovelli studied medicine at the “Sapienza” University of Rome, Italy. At the same University, he specialized in medical oncology and had the PhD in molecular medicine and human pathology. He has international experience as a fellow at the Institute Gustave Roussy in France and as an oncologist in main referral oncological centres in Italy. Currently, he is a medical oncologist at the University Hospital of Verona, Italy. His research activities focus on metastatic renal cell carcinoma, prostate, and bladder cancer. His major interest is in predictive and prognostic factors in GU cancers as well as the sequence of therapy in renal cancer. He has published more than one hundred papers in international peer-reviewed journals and several abstracts at international conferences on these topics. Dr Iacovelli has received many national and international awards, such as the ASCO Cancer Foundation Merit Award in 2011 and the best poster award at the ESMO congress in 2012.
Dr Roberto Iacovelli has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Astellas, Ipsen, Janssen, Merck, Pfizer and Sanofi.
|
5 min
|
Oct 2021
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.